Duopharma Biotech Bhd Working Capital to Net Assets Ratio
Duopharma Biotech Bhd working capital to net assets ratio. Duopharma Biotech Bhd (7148) has a Working Capital to Net Assets ratio of 69.0% as of June 2026. Working capital of RM542.75 Million (current assets of RM844.09 Million minus current liabilities of RM301.34 Million) is measured against net assets of RM786.14 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Duopharma Biotech Bhd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Duopharma Biotech Bhd (2006–2025)
Working capital to net assets ratio of Duopharma Biotech Bhd from 2006 to 2025. This chart shows how Duopharma Biotech Bhd's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of June 2026, the ratio stands at 69.0%, reflecting working capital of RM542.75 Million against net assets of RM786.14 Million MYR. See defensive interval ratio of Duopharma Biotech Bhd to measure how many days the company can operate on defensive assets alone.
Duopharma Biotech Bhd Working Capital to Net Assets Ratio by Year (2006–2025)
Duopharma Biotech Bhd working capital to net assets ratio by year from 2006 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Duopharma Biotech Bhd from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Duopharma Biotech Bhd balance sheet assets.
| Year | WC/NA Ratio | Working Capital (MYR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 66.7% | RM505.45 Million | RM757.62 Million | RM819.41 Million | RM313.96 Million | ▼ -10.8 pp |
| 2024 | 77.5% | RM549.62 Million | RM709.15 Million | RM727.05 Million | RM177.43 Million | ▲ +3.2 pp |
| 2023 | 74.3% | RM510.34 Million | RM687.12 Million | RM677.07 Million | RM166.73 Million | ▲ +32.0 pp |
| 2022 | 42.3% | RM276.90 Million | RM655.22 Million | RM541.49 Million | RM264.59 Million | ▼ -0.1 pp |
| 2021 | 42.4% | RM264.49 Million | RM624.00 Million | RM494.80 Million | RM230.31 Million | ▼ -5.7 pp |
| 2020 | 48.1% | RM309.37 Million | RM643.82 Million | RM459.69 Million | RM150.32 Million | ▲ +14.5 pp |
| 2019 | 33.6% | RM177.76 Million | RM529.75 Million | RM417.20 Million | RM239.44 Million | ▲ +3.4 pp |
| 2018 | 30.1% | RM144.88 Million | RM481.04 Million | RM367.33 Million | RM222.44 Million | ▼ -18.8 pp |
| 2017 | 49.0% | RM234.96 Million | RM479.87 Million | RM356.62 Million | RM121.66 Million | ▼ -8.9 pp |
| 2016 | 57.9% | RM263.03 Million | RM454.52 Million | RM366.18 Million | RM103.16 Million | ▼ -4.3 pp |
| 2015 | 62.2% | RM279.63 Million | RM449.72 Million | RM354.35 Million | RM74.71 Million | ▲ +19.1 pp |
| 2014 | 43.1% | RM83.51 Million | RM193.63 Million | RM106.85 Million | RM23.35 Million | ▲ +1.7 pp |
| 2013 | 41.4% | RM75.63 Million | RM182.65 Million | RM94.19 Million | RM18.55 Million | ▼ -0.1 pp |
| 2012 | 41.5% | RM70.75 Million | RM170.50 Million | RM92.62 Million | RM21.87 Million | ▼ -1.3 pp |
| 2011 | 42.8% | RM70.41 Million | RM164.44 Million | RM95.82 Million | RM25.41 Million | ▼ -2.7 pp |
| 2010 | 45.5% | RM71.86 Million | RM157.87 Million | RM96.23 Million | RM24.37 Million | ▼ -11.6 pp |
| 2009 | 57.1% | RM81.54 Million | RM142.74 Million | RM98.52 Million | RM16.98 Million | ▼ -3.4 pp |
| 2008 | 60.5% | RM78.97 Million | RM130.55 Million | RM95.01 Million | RM16.04 Million | ▲ +9.4 pp |
| 2007 | 51.1% | RM58.38 Million | RM114.21 Million | RM67.76 Million | RM9.38 Million | ▼ -12.5 pp |
| 2006 | 63.6% | RM92.53 Million | RM145.43 Million | RM103.27 Million | RM10.74 Million | — |